In this study the investigators would like to study systemic and regional disturbances in patients with sepsis-associated acute kidney injury and in healthy controls undergoing laparoscopic abdominal surgery. Specifically study metabolic, hemodynamic and oxygen transport variables.

开始日期2023-08-14

申办/合作机构-

NCT05507892

/ Recruiting临床2期IIT

Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease

Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel function in patients with type 2 diabetes. However, it is unknown how canagliflozin protects the kidneys from disease. Therefore, this study plans to learn more about how canagliflozin works to protect against diabetic kidney disease in adults with type 2 diabetes. This study will use state-of-the-art kidney imaging, kidney biopsies and detailed testing of kidney function to determine the mechanisms of protection afforded by canagliflozin.

开始日期2022-10-10

申办/合作机构

University of Colorado Denver

[+1]

NCT05530356

/ Enrolling by invitationN/AIIT

Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes: A Follow-up Study

The current protocol plans to enroll participants with youth-onset Type 2 Diabetes (T2D) as well as obese and lean controls from the Renal-HEIR - Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study (n=100) [COMIRB #16-1752] in a prospective investigation that seeks to 1) define the changes in kidney function by gold standard techniques and energetics by functional Magnetic Resonance Imaging (MRI) in adolescents with and without T2D as they transition to young adulthood; 2) quantify kidney oxidative metabolism by 11C-acetate Positron Emission Tomography (PET) in a subset of participants who are ≥18 years of age with youth-onset T2D and/or obesity; 3) determine peripheral arterial stiffness by SphygmoCor. Mechanistic insight will be provided by transcriptomic analyses of repeat biopsies 3-years after their initial biopsy for eligible participants with youth-onset T2D, as well as molecular analysis of tissue obtained from J-wire endovascular biopsies. This study will also leverage this well-characterized cohort of youths to define youth-onset T2D-related changes in brain morphology and function by structural MRI and resting-state functional MRI and through the assessment of cognitive function (fluid and crystallized intelligence) using the NIH Toolbox Cognitive Battery (NIHTB-CB), as an exploratory objective. All enrollees in Renal-HEIR have consented to be contacted for future research opportunities.

开始日期2022-09-30

申办/合作机构

University of Colorado Denver

100 项与氨基马尿酸钠相关的临床结果

登录后查看更多信息

100 项与氨基马尿酸钠相关的转化医学

登录后查看更多信息

100 项与氨基马尿酸钠相关的专利（医药）

登录后查看更多信息

1,274

项与氨基马尿酸钠相关的文献（医药）

2026-06-01·MARINE POLLUTION BULLETIN

Spatial contaminant assessment (PAHs, PCBs, OCs, PBDEs) and lipid composition in Beaufort Sea (2011−2020) and Chukchi Sea polar bear (2015–2016) subpopulations, Alaska, USA

Article

作者: Adams, Billy ; Miller, Christelle ; Sherwood, Tracy A ; Stimmelmayr, Raphaela ; Schloesser, Ryan ; Wetzel, Dana L

Polar bears, as apex predators, serve as indicators of Arctic ecosystem health and are an essential cultural and nutritional subsistence resource for coastal-dwelling Alaska Natives. We compared adipose tissue contaminant burden and lipid metabolism of two Alaskan polar bear subpopulations: the Southern Beaufort Sea (SB) (2011-2020) and the adjacent Chukchi Sea (CS) (2015-2016), and investigated the relationships between contaminant concentrations and lipid composition in adipose tissue. Contaminant profiling revealed significant differences between the two subpopulations. The CS bears had higher concentrations of polycyclic aromatic hydrocarbons (∑PAHs), whereas the SB bears had higher polychlorinated biphenyls (∑PCBs) and polybrominated diphenyl ethers (∑PBDEs), but not in organochlorine pesticides (∑OCs), whereas individual OCs differed significantly. The temporal trend for total contaminant burden showed a steady decline in SB bears over the 10-year period. Lipid metabolism differed significantly between subpopulations and across age classes within the CS polar bears. Pearson's coefficients indicated a positive correlation between ∑PCBs and percent triglycerides (%TGs) and a strong negative correlation between ∑PAHs and %TGs for all bears. This study provides important point-in-time and temporal trend data for key organic contaminants (PCBs, OCs, PBDEs) and PAHs for these two subpopulations. We also provide correlational field evidence that links PCB and PAH exposure to alterations in lipid metabolism in both SB and CS polar bears. From a northern One Health perspective continued contaminant monitoring in Alaskan polar bear subpopulations is warranted particularly under a rapidly changing Arctic where contaminant cycling and exposure of biota from ongoing climate-driven sea ice loss is predicted to increase.

2026-05-01·SCIENCE OF THE TOTAL ENVIRONMENT

Impact of traffic-related air pollution exposure on fractional exhaled nitric oxide: A systematic review and Meta-analysis

Review

作者: Assavanopakun, Pheerasak ; Chaiwarut, Matina ; Hannarong, Chutharat ; Lehnu, Naowaf ; Kiratipaisarl, Wuttipat

BACKGROUND:

Traffic-Related Air Pollution (TRAP) is a complicated mix of gases and particulates associated with respiratory oxidative stress and immunological dysfunction. FeNO (Fractional exhaled Nitric Oxide) is emerging as an essential biomarker for inflammation. The duration, specific exposure patterns, and magnitude of associations of FeNO with TRAP remain unclear. This research synthesizes and analyzes the evidence linking specific TRAP to FeNO alteration in human population.

METHODS AND RESULTS:

A systematic review across 3 databases: PubMed, Scopus and Embase, until 3 February 2026, yields a qualitative synthesis of 48 papers, with a majority reporting increase in FeNO levels with various TRAP exposure (33 out of 48, 71.1%). A network meta-analysis of 9 studies (n = 5761) across a network of 10 pollutants found black carbon (BC, 10.8, 95% CI (confidence interval): 2.1, 20.2) and polycyclic aromatic hydrocarbons (PAH, 9.5, 95% CI: 0.8, 18.9) as the pollutant associated with the highest 24-h percent FeNO difference per interquartile range (IQR) of pollutants. Heterogenous results may related to confounders and effect modifiers affecting FeNO, such as demographic differences, follow-up time inconsistencies, varying baseline FeNO levels and IQR of pollutants.

DISCUSSION AND CONCLUSION:

FeNO may serve as a biomarker for adverse health effects from TRAP exposure for BC and PAH. Consistent approach for defining air pollutants components and measurement units is advocated for future research to be cohesive. Though a short term 24-h for FeNO level is the most common, future research should standardize protocol of follow-up time and confounder adjustments to ensure comparability of the statistical estimates across other time points.

2026-05-01·ENVIRONMENTAL POLLUTION

Polycyclic aromatic hydrocarbon exposure and mitochondrial DNA copy number: Opposing roles of oxidative stress and inflammation

Article

作者: Li, Juntao ; Yuan, Jun ; He, Jia ; Su, Wenzhe ; Zhou, Si ; Zeng, Lingli ; Tan, Lei ; Peng, Rongfei

Previous studies indicate that exposure to polycyclic aromatic hydrocarbons (PAHs) may impair mitochondrial function and induce oxidative stress and inflammation. However, the associations of PAH exposure with mitochondrial DNA and related biological responses remain largely unexplored. In this study, we assessed the association between urinary hydroxylated polycyclic aromatic hydrocarbon metabolites (OH-PAHs) and blood mitochondrial DNA copy number while exploring the potential mediating roles of oxidative stress and inflammatory markers. We determined urinary concentrations of OH-PAHs, 8-hydroxy-2'-deoxyguanosine, and 8-hydroxyguanosine, and measured white blood cell count in whole blood of 385 participants. The relative mitochondrial DNA copy number was assessed by real-time quantitative polymerase chain reaction using two mitochondrial target genes normalized against three reference genes. Urinary OH-PAHs and oxidative stress markers showed a significant increasing trend with age, whereas white blood cell counts were not significantly associated with age. Multivariable linear regression models demonstrated that 3-hydroxyfluorene and 4-hydroxyphenanthrene were consistently positively associated with mitochondrial DNA abundance. Mixture effect analysis indicated that higher quantiles of urinary concentrations of OH-PAHs were associated with increased mitochondrial DNA copy number across different normalization genes. Mediation analysis showed that urinary OH-PAHs were positively associated with mitochondrial DNA copy number, yet the indirect effect mediated through oxidative stress was in the opposite direction to the direct effect. In contrast, the indirect effect through inflammation was consistent with the direct effect. The results indicated that oxidative stress exhibited a suppression effect on the association between PAH exposure and mitochondrial DNA copy number, whereas inflammatory markers acted as mediators in these associations.

项与氨基马尿酸钠相关的新闻（医药）

2026-04-15

·EINPresswire

Heart-lung transplant saves woman with rare form of pulmonary hypertension

Donna Parks first noticed something was off back in 2014 during everyday tasks like taking out the garbage. “I was out of breath,” said Parks, now 47, who worked as a rehabilitation caregiver in Detroit at the time. “Something wasn't right; I shouldn't have been tired walking 15 steps to the curb.” A pulmonologist diagnosed Parks with pulmonary arterial hypertension, or PAH — a serious condition where arteries in the lungs become damaged and narrowed. This makes it harder for blood to flow through the lungs, forcing the right side of the heart to work extra hard. Over time, this strain can cause the heart to fail, leading to fluid buildup, kidney problems and even death if untreated. “PAH is one of the rarest but most lethal forms of pulmonary hypertension ,” said Manreet Kanwar, MD , a cardiologist and director of the Heart Failure and Pulmonary Hypertension program at the University of Chicago Medicine. Symptoms of pulmonary hypertension include shortness of breath, fluid retention, fatigue, rapid heartbeat and even loss of consciousness. But many other conditions have these same symptoms, which can make the disease tough to diagnose. In Parks’ case, doctors couldn’t pinpoint what caused her condition. Treatment, then transplant surgery There is no cure for PAH, but medications can slow its progression. Parks was prescribed several drugs, including epoprostenol, to help relax the blood vessels in the lungs. Her symptoms improved at first but worsened over the last two years. “The numbers weren’t getting better,” Parks said. By 2025, the left side of Parks’ heart also began to fail. Doctors told her the only option was a heart and lung transplant . But Parks faced a tough challenge: She was highly sensitized, meaning her immune system had developed many antibodies that made it difficult to find donor organs her body would accept. Several hospitals considered her too high-risk for transplant, so she turned to UChicago Medicine — one of the few centers in North America experienced in transplants for highly sensitized patients. “She was essentially walking around in a state of low-grade shock at all times,” said UChicago Medicine pulmonologist Scott Vasher, MD . “It was amazing she felt as well as she did.” Parks temporarily moved to Chicago, where doctors used plasmapheresis — a treatment that filters a person’s blood to remove the problematic antibodies before and after surgery. After six weeks in the hospital, Parks got the call last September: A matching heart and lungs were available. Parks underwent a 12-hour surgery at UChicago Medicine to remove and replace her diseased heart and lungs. Team effort for double-organ transplant During the 12-hour operation, Parks was connected to a machine that took over her heart and lung functions. Working together, heart surgeon Valluvan Jeevanandam, MD , and thoracic surgeon Pablo Sanchez, MD, PhD , removed her diseased heart and lungs in one piece. “It’s a little like changing the engine block of a car,” said Sanchez, the surgical director of UChicago Medicine’s Lung Transplant Program . “You take the whole engine out, and there’s this big empty space.” The surgeons carefully placed the donor organs and reconnected the trachea, aorta and vena cavas. Parks was gradually taken off the bypass machine, and her chest was closed. She then spent another six weeks recovering in the hospital. “All aspects of care — the surgery, the preoperative and postoperative care, the immunology — had to work perfectly in unison for a good outcome,” said Jeevanandam, director of the UChicago Medicine Heart & Vascular Center . “Fortunately, that’s what the UCM team is recognized around the world for: having great results on cases no one else can or is willing to tackle.” Ready for the road ahead Today, Parks uses a walker and attends rehab therapy twice a week at UChicago Medicine’s Duchossois Center for Advanced Medicine in Hyde Park. She’s feeling stronger and looks forward to reducing the many immunosuppressant medications she needs to keep her new heart and lungs healthy. She is also eager to see her 93-year-old mom — who Parks credits for her tenacity — once she recovers and returns to Detroit. Parks is grateful to the individuals who consented to donate their organs upon their deaths. "I am so glad people are willing to help other people like me," she said. "They didn't have to donate, and they chose to. Because of that, they are giving someone else a chance to live." Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2026-03-30

·adalvo.com

Adalvo advances DCP review for Ambrisentan + Tadalafil fixed-dose combination tablets

Adalvo continues to progress its Ambrisentan + Tadalafil film-coated tablets towards MA approval in Q1 2027. This first-of-its-kind fixed-dose combination (FDC) therapy is indicated to treat Pulmonary Arterial Hypertension (PAH) in adult patients. Pulmonary Arterial Hypertension (PAH) is a rare, progressive condition that can lead to right heart failure. It most commonly affects women aged 30 to 60, and while there's no cure, current treatments can help manage symptoms, slow disease progression and improve quality of life. The combination of Ambrisentan (an endothelin receptor antagonist) and Tadalafil (a PDE5 inhibitor) is a potent, dual-action therapy. The landmark AMBITION study found that the combined therapies delivered superior efficacy, reduced the risk of clinical failure events by 50%, and improved exercise capability. Reflecting guideline recommendations around upfront combination therapy, Adalvo is developing the FDC in the full range of strengths: 5mg+20mg, 5mg+40mg, 10mg+40mg. This benefits both prescribers and patients; patients remain on a single tablet throughout titration rather than switching to separate tablets during dose adjustment. And it means prescribers can offer a convenient, proven, and differentiated once-daily oral treatment, helping to improve adherence. The global PAH treatment market is projected to reach approximately $13.3 billion by 2033, reflecting a CAGR of around 5.9% from 2025. This growth reflects increasing diagnosis rates, improved awareness and an expanding treatment landscape. According to IQVIA, combined global sales of Ambrisentan and Tadalafil brands exceeded $3 billion in 2025. To explore partnership opportunities for Ambrisentan + Tadalafil fixed-dose combination tablets, or to discover Adalvo's cardiovascular and rare disease portfolio, contact one of the team today.

上市批准

2026-03-02

·365医学网

年度盘点｜华潞：2025年肺动脉高压学术进展年度报告：从分子机制到临床诊疗范式的全面回顾

本文特邀：作者：谭江山[1]，华潞[2] 单位：中国医学科学院阜外医院[1]，中国医学科学院阜外医院深圳医院[2] 2025年标志着肺动脉高压（Pulmonary Arterial Hypertension, PAH）诊疗领域的一个历史性转折点。随着对BMPR2信号通路失调、内皮细胞焦亡（NLRP3/GSDME轴）以及溶酶体-线粒体细胞器通讯障碍等分子机制的深入解析，PAH的病理生理学图谱得到了前所未有的完善。在治疗方面，以Sotatercept为代表的激活素信号传导抑制剂通过STELLAR、ZENITH及HYPERION等关键III期临床试验，确立了其作为首个“疾病修饰（Disease Modification）”药物的地位，显著降低了肺血管阻力并改善了高危患者的生存预后。临床策略正从传统的血管舒张治疗向靶向血管重塑逆转演进，强调早期干预与精准分层。此外，人工智能（AI）辅助的无创血流动力学评估（如4D Flow MRI）与多组学技术的整合，为实现PAH的精准医学奠定了坚实基础。本报告旨在系统梳理2025年度PAH领域的重大突破，为未来的临床实践与科研方向提供科学指引。 1.引言：范式转移的临界点长期以来，PAH的治疗策略主要集中于纠正内皮素、一氧化氮和前列环素这三条经典通路的失衡，其核心效应在于促进肺血管舒张。然而，这类疗法虽能改善血流动力学参数和运动耐量，却难以从根本上逆转肺血管重塑（Pulmonary Vascular Remodeling）这一核心病理改变。 2025年，随着分子生物学机制研究的突破性进展以及新型靶向药物临床数据的公布，PAH的治疗目标正式迈入“疾病修饰”的新纪元。国际学术界对治疗成功的定义已不再局限于六分钟步行距离（6MWD）的增加，而是提升至右心室-肺动脉耦联（RV-PA Coupling）的恢复及长期生存率的改善1。 2.分子机制与遗传学：从信号转导到细胞器稳态 2025年的基础研究不仅深化了对经典信号通路的理解，更将视野拓展至细胞器互作与代谢重编程的精细调控网络。 2.1 内皮细胞焦亡与炎症级联反应血管炎症是PAH进展的关键驱动力。2025年的研究首次揭示了NLRP3/GSDME介导的内皮细胞焦亡（Pyroptosis）机制2。（1）机制解析：BMPR2信号缺失直接激活NLRP3炎症小体，进而切割Gasdermin E（GSDME）蛋白，在细胞膜上形成孔洞，诱导内皮细胞发生程序性焦亡。（2）病理后果：焦亡细胞释放大量白细胞介素-1β（IL-1β），形成正反馈回路，加剧血管壁的炎性浸润与平滑肌细胞的异常增殖。动物模型显示，靶向抑制NLRP3或GSDME可显著减轻右心室收缩压及血管重塑，为抗炎治疗提供了精确靶点。 2.2 细胞器通讯障碍：溶酶体-线粒体轴 2025年发表于《Science》的一项里程碑研究，将PAH的发病机制推进至细胞器稳态层面3。（1）NCOA7的关键作用：研究发现，核受体共激活因子7（NCOA7）的缺失会导致肺血管细胞内溶酶体酸化功能受损，阻滞自噬流。（2）跨细胞器应激：溶酶体功能障碍通过信号级联反应诱发线粒体动力学失衡及氧化应激，这种“溶酶体-线粒体轴”的通讯崩溃，驱动了血管细胞向类似肿瘤的促增殖、抗凋亡表型转化。这一发现确立了恢复细胞器稳态作为逆转血管重塑的新策略。 3.治疗突破：Sotatercept与疾病修饰疗法的临床确证 2025年是PAH药物研发的丰收之年，以Sotatercept为代表的创新药物通过调节TGF-β超家族信号平衡，实现了从“血管舒张”向“逆转重塑”的跨越。 3.1 Sotatercept的作用机制与药理学特征 Sotatercept是一种首创的（First-in-class）活化素受体IIA型（ActRIIA）-Fc融合蛋白。其作用机制为“配体捕获”（Ligand Trap），即通过结合并中和过量的活化素A/B（Activin A/B）及生长分化因子（GDF8/11），阻断其与内源性受体的结合，从而抑制下游促增殖、促纤维化的Smad2/3信号，恢复BMPR2介导的抗增殖信号平衡。这从根本上纠正了驱动PAH血管重塑的分子缺陷。 3.2 关键III期临床试验数据综述 3.2.1 ZENITH试验：高危人群的生存获益 ZENITH试验针对REVEAL Lite 2评分≥9的高危患者，因疗效显著而提前终止，提供了最为震撼的生存数据4：（1）复合终点降低： Sotatercept组发生死亡、肺移植或因PAH恶化住院的风险较安慰剂组降低了76%。（2）临床意义：这是首次有药物在预后极差的高危PAH人群中证实能大幅降低硬终点事件，标志着其在高危管理中的基石地位。 3.2.3 HYPERION试验：早期干预的价值针对确诊1年内的早期患者，HYPERION研究证实，在标准治疗基础上早期加用Sotatercept，可将临床恶化风险降低至11%（对照组37%，HR 0.24, p<0.001）5。这一结果有力支持了在疾病早期即启动疾病修饰治疗的策略。 3.3 长期安全性与SOTERIA研究 AHA 2025会议公布的汇总分析及SOTERIA扩展研究（中位随访2.5年）表明，Sotatercept具有良好的长期耐受性6,7。常见不良事件包括毛细血管扩张（Telangiectasia）、轻度鼻出血及血红蛋白升高，未发现新的严重安全性信号。这为其作为长期维持治疗药物提供了保障。 4.临床诊疗策略的演进与优化基于上述证据，PAH的临床管理策略在2025年经历了深刻的重构。 4.1 治疗范式的转变（1）从“阶梯治疗”到“早期联合与疾病修饰”：传统的单药起始、按需加量的模式已被摒弃。HYPERION数据支持在诊断确立后的早期（<1年）即引入Sotatercept，以最大程度遏制血管重塑进程5。（2）高危患者的激进管理：对于高危患者，ZENITH研究确立了以Sotatercept为核心的强化治疗方案，旨在快速降低PVR，逆转右心室重构，避免过早进入移植等待名单4。 4.2 真实世界中的实施差距尽管指南推荐积极治疗，但2025年的一项大规模回顾性队列研究（N=2853）揭示了严峻的现实差距：超过50%的新诊断患者仍仅接受单药治疗，且双重/三重联合治疗的普及率在不同专科（心血管科 vs. 呼吸科）间存在显著差异8。弥合这一“循证-实践”鸿沟是未来卫生政策的重点。 4.3 临床终点的重新定义专家共识指出，单一的6MWD已不足以评估新型药物的全面获益。未来的临床试验终点将更侧重于复合临床恶化事件（Time to Clinical Worsening）、右心室结构逆转指标及长期生存率，以匹配疾病修饰疗法的深度效应1。 5.精准医学与新型技术应用 2025年，PAH诊疗进入了以多组学整合与人工智能为特征的精准医学时代。 5.1 免疫表型化与靶向干预 SATISFY-JP研究探索了IL-6受体拮抗剂Satralizumab在特定炎症表型PAH患者中的疗效，开启了基于免疫特征分型的精准治疗先河9。这表明，未来的治疗将不再是“一种药物适用所有人”，而是基于患者的免疫炎症谱进行个体化给药。 5.2 影像学技术的革新（1）4D Flow MRI：这种技术不仅能成像，还能定量分析肺动脉内的血流动力学参数（如涡流持续时间、壁面剪切应力）。研究表明，主肺动脉涡流特征与平均肺动脉压（mPAP）高度相关，可作为无创监测血管重塑的敏感指标10。（2）AI增强超声（MePH模型）：这是一个多模态视觉语言模型，通过整合超声视频与临床元数据，其预测mPAP和PVR的准确性显著优于传统人工测量（MAE降低约45%，诊断AUC达0.921），大幅降低了对有创右心导管检查的依赖11。 6.流行病学特征与公共卫生挑战全球疾病负担研究（GBD）数据揭示了PAH流行病学的动态变化12：（1）老龄化趋势：疾病负担正向老年人群显著转移，特别是在高社会人口指数（SDI）国家，这增加了合并症管理的复杂性。（2）性别差异：女性患病率持续高于男性，但男性患者往往预后更差，这种“生存悖论”背后的性激素调节机制仍需深入探索。（3）地域不平等：中低SDI地区承担了全球最高的疾病负担（如东非、南亚），诊断延迟与药物可及性差仍是主要瓶颈。 7.结论与展望综上所述，2025年是肺动脉高压领域具有里程碑意义的一年。Sotatercept的成功不仅仅是一个新药的上市，更验证了通过纠正分子信号失衡来逆转血管重塑这一科学假说的正确性。展望未来，PAH的研究与临床实践将聚焦于以下方向：（1）精准分型：利用多组学和AI技术，识别对特定靶向药物（如HDAC抑制剂、免疫调节剂）敏感的亚群。（2）长期安全性监测：持续关注新型生物制剂在长期应用中的安全性与耐药性问题。（3）全球可及性：推动高价值药物在不同经济水平地区的公平获取。 PAH正在经历从一种“进行性、致死性疾病”向“可控、可逆转慢性病”的蜕变。科学界的共同愿景是，利用现有的疾病修饰武器，最终实现患者生理学和功能学意义上的全面康复。学术关键词肺动脉高压，分子机制诊疗，精准分型，内皮细胞焦亡，炎症级联反应，细胞器通讯障碍，Sotatercept 年度盘点学术特辑扫码查看更多内容参考文献（上下滑动阅览） 1.Rahaghi FF, Humbert M, Hoeper MM, et al. Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients. The Lancet Respiratory medicine 2025;13(4):364-370. (In eng). DOI: 10.1016/s2213-2600(24)00425-9. 2.Tian XT, Peng ZY, Wu YS, et al. Loss of Type 2 Bone Morphogenetic Protein Receptor Activates NOD-Like Receptor Family Protein 3/Gasdermin E-Mediated Pyroptosis in Pulmonary Arterial Hypertension. Journal of the American Heart Association 2025;14(3):e034726. (In eng). DOI: 10.1161/jaha.124.034726. 3.Harvey LD, Alotaibi M, Tai YY, et al. Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension. Science (New York, NY) 2025;387(6732):eadn7277. (In eng). DOI: 10.1126/science.adn7277. 4.Presented by Vallerie V. McLaughlin M, FACC, at the American Heart Association Scientific Sessions (AHA 2025), New Orleans, LA, Nov. 8, 2025. 5.McLaughlin VV, Hoeper MM, Badesch DB, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. The New England journal of medicine 2025;393(16):1599-1611. (In eng). DOI: 10.1056/NEJMoa2508170. 6.Thakur T CJ, Watzker A, Lautsch D. Overall survival of patients on sotatercept: an analysis of STELLAR and SOTERIA trials. Presented at: ATS 2025 International Conference; May 19, 2025; San Francisco, CA. https://www.atsjournals.org/doi/10.1164/ajrccm.2025.211.Abstracts.A4975. 7.Preston IR G-MM, Hoeper MM, et al. Long-term safety and exposure-adjusted incidence rates of adverse events from pooled sotatercept studies (PULSAR, SPECTRA, STELLAR, and SOTERIA). Presented at: ATS 2025 International Conference; May 19, 2025; San Francisco, CA. https://www.atsjournals.org/doi/10.1164/ajrccm.2025.211.Abstracts.A4981. 8.Sahay S, Sisk M, Nelsen A, Wu B, Ryan J. Real-world use of initial combination treatment in the management of pulmonary arterial hypertension. Therapeutic advances in respiratory disease 2025;19:17534666251390070. (In eng). DOI: 10.1177/17534666251390070. 9.Investgators P. Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) | ClinicalTrials.gov aF, 2026, https://clinicaltrials.gov/study/NCT05934526. 10.Horvat D, Orzan RI, Agoston-Coldea L. A Non-Invasive Approach to Pulmonary Hypertension. Journal of clinical medicine 2025;14(5) (In eng). DOI: 10.3390/jcm14051473. 11.Yang J, Huang T, Ding S, et al. AI-Enabled Accurate Non-Invasive Assessment of Pulmonary Hypertension Progression via Multi-Modal Echocardiography. 2025. 12.Wu C, Wang Z, Luo Y, et al. Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 and projection to 2050: A systematic analysis for the global burden of disease study 2021. PloS one 2025;20(12):e0338335. (In eng). DOI: 10.1371/journal.pone.0338335. 声明：本文为学术进展综述，旨在传播医学信息，不构成任何具体的诊疗建议。如有疾病诊疗需求，请前往正规医疗机构就诊。专家简介华潞 | 主任医师中国医学科学院阜外医院深圳医院（点击进入专家个人空间）中国医学科学院阜外医院深圳医院，主任医师，硕士研究生导师，国家心血管疾病临床医学研究中心PI，中国医学科学院阜外医院深圳医院内科管委会副主任，肺血管病房主任，中国医学科学院阜外医院深圳医院临床研究中心副主任。中国医疗保健国际交流促进会心脏重症分会副主任委员，中国毒理学会临床毒理专业委员会常务委员，中国研究型医院学会血栓与止血专业委员会常务委员等。从事心肺血管疾病和血栓性疾病的诊治工作20余年，在全国率先开设“血栓性疾病和肺动脉高压遗传门诊”，进行遗传咨询、基因报告解读、生育指导等。国家“十五”863课题、“十一五”国家重大专项课题、 “十二五”国家科技重大专项课题的主要完成人，主持/参与完成50个心血管新药的65项国际、国内I-IV期心血管药物临床研究，评价药物的有效性和安全性。作为主要完成人获得首届中国药学会科学技术二等奖、北京市科学技术奖三等奖。在《Eur Heart J》等期刊发表论文130多篇，主编和参编学术专著5部。专家简介谭江山 | 住院医师中国医学科学院阜外医院（点击进入专家个人空间）住院医师，临床博士后，医学博士，中国医学科学院阜外医院，心内科。主要方向为心肺血管疾病的机制与临床。中国营养协会发育障碍与营养治疗分会委员、党小组成员，担任JTIM、Cardiovascular Theraputics等杂志的编委/青年编委。主持国自然青年项目和中央高水平医院项目；在European Heart Journal等期刊发表SCI论文30余篇。欢迎扫码入群交流长按识别二维码，即可进入沟通交流群专栏合集行业要闻｜创新研究文章｜课件｜视频｜音频高血压｜心脏重症｜心力衰竭｜冠心病｜瓣膜｜心律失常｜周围血管｜心电生理指南共识｜学术荟萃｜人物专访｜新心联播｜2025年度盘点 ESC 2025｜CSC 2025｜TCT2025 点击合集名称，查看更多内容👆👆👆 END 声明：本站旨在分享医学专业信息，仅供医疗卫生行业专业人士阅读参考，不针对普通大众。文内信息版权属于持有人，所有信息仅供学术参考，不构成任何医疗决策和诊疗依据，如遇健康问题请前往正规医院就诊。本站发布内容和观点不代表本站立场，如有侵权，请联系我们删除。未经许可，禁止转载。投稿/会议发布，请联系editor@365yixue.com kefu@365yixue.com 点击下方卡片 / 获取更多内容点击“阅读原文”，开启学习之旅！

临床3期

100 项与氨基马尿酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01421	氨基马尿酸钠	V04CH30	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾脏疾病	日本	Alfresa Pharma Corp.	1951-08-16
诊断试剂	美国	Merck & Co., Inc.	1944-12-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03618420 (CASPER, CTgov)	临床1/2期	1型糖尿病 \| 糖尿病肾病	50	Iohexol Inj 300 mg/mL+Aminohippurate Sodium Inj 20%	繭齋鹹顧顧獵獵醖顧網(壓淵窪淵衊願衊遞簾選) = 鏇願顧遞鏇壓夢窪鹽獵製襯築淵衊鹽遞願鑰鹹 (餘壓構襯蓋製繭獵鹹壓, 5.0) 更多	-	2021-08-31